Clinical Trials Directory

Trials / Sponsors / Seaside Therapeutics, Inc.

Seaside Therapeutics, Inc.

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
TerminatedAn Open Label Extension Study in Subjects With Fragile X Syndrome
Fragile X Syndrome
Phase 32011-11-01
TerminatedOpen Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Autism Spectrum Disorders
Phase 32011-11-01
CompletedEfficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragi
Fragile X Syndrome
Phase 32011-06-01
CompletedEfficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile
Fragile X Syndrome
Phase 32011-05-01
CompletedStudy of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Autism Spectrum Disorders
Phase 22011-05-01
SuspendedA Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
Fragile X Syndrome
Phase 22011-05-01
TerminatedAn Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Autism Spectrum Disorders
Phase 22010-02-01
TerminatedAn Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Fragile X Syndrome
Phase 22009-11-01
CompletedA Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
Fragile X Syndrome
Phase 12009-09-01
CompletedBiomarker and DNA Collection in Subjects Participating in Protocol 22003
Fragile X Syndrome
—2009-05-01
CompletedOpen-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Autism Spectrum Disorders
Phase 22009-02-01
CompletedBiomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Fragile X Syndrome
—2009-01-01
CompletedSafety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Fragile X Syndrome
Phase 22008-11-01